Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colloidal pectin bismuth + metronidazole + tetracycline + omeprazole
- Development stage
- Unknown
- Lead developer
- Xijing Hospital of Digestive Diseases
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A bismuth-containing quadruple therapy (BQT) regimen consisting of colloidal pectin bismuth, the proton pump inhibitor omeprazole, and the antibiotics metronidazole and tetracycline. This specific combination is being evaluated by the Xijing Hospital of Digestive Diseases for the first-line treatment of Helicobacter pylori infection. Colloidal pectin bismuth provides a mucosal protective effect and exerts direct antimicrobial activity against H. pylori by interfering with bacterial enzymes and cell wall integrity. Omeprazole increases gastric pH, which stabilizes the antibiotics and improves their efficacy. Metronidazole and tetracycline act synergistically to inhibit bacterial DNA and protein synthesis, respectively, helping to overcome antibiotic resistance common in H. pylori strains.
- Other names
- Pectin bismuth-based quadruple therapyPB-MTO regimen
02
Targets
Bacterial RibosomeATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on colloidal pectin bismuth + metronidazole + tetracycline + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colloidal pectin bismuth + metronidazole + tetracycline + omeprazole.